BioSpace News Archive

Ergomed plc will announce its interim results for the six months ending 30 June 2019 on 25September 2019.

The 25th annual BIO-Europe® global life sciences partnering event will be held November 11–13, 2019, in Hamburg, Germany, supported by regional hosts Life Science Nord, the City of Hamburg, and the State of Schleswig-Holstein.

The trials met the primary endpoints, with ofatumumab demonstrating a highly significant and clinically meaningful decrease in the number of confirmed relapses. The trials also hit key secondary endpoints, delaying the time to confirmed disability progression.

In an ongoing battle between Regeneron Pharmaceuticals and Sanofi versus Amgen over PCSK9 inhibitors to treat high cholesterol, a U.S. district court invalidated Amgen’s patents for Repatha.

WntResearch and The Sage Group have initiated a collaboration to accelerate the process of identifying and engaging potential partners prior to readout of the on-going Phase 2 study with Foxy-5.

Innovent Biologics, Inc. announced that the clinical trial results of IBI303, an anti-tumor necrosis factor-alpha monoclonal antibody injection developed by Innovent, has been published in The Lancet Rheumatology, a leading international medical journal, with comment by Stanley Cohen, professor of University of Texas Southwestern Medical Center.

AAC Holdings, Inc. announced financial results for the second quarter and six months ended June 30, 2019, as well as updated 2019 guidance.

Constellation Alpha Capital Corp. and DermTech Operations, Inc. announced that they have completed their previously announced business combination.

Allergan plc announced that the Company and its U.S. subsidiaries have reached a settlement with plaintiffs scheduled for trial in October 2019 in the federal opioid multidistrict litigation.

Tolk Chiropractic & Wellness launches Tolk Rewards, a digital rewards program that gives back to loyal patients